News from NeuroSigma A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 10, 2015, 07:00 ET

Preliminary Results Utilizing NeuroSigma's Monarch eTNS System for the Treatment of Traumatic Brain Injury Presented at the North American Neuromodulation Society Annual Meeting

 NeuroSigma, Inc. (NeuroSigma), today announced positive preliminary findings from a clinical study using non-invasive external Trigeminal...

Nov 16, 2015, 05:00 ET

NeuroSigma's Monarch eTNS System Receives CE Mark Approval for ADHD

NeuroSigma®, Inc. (NeuroSigma) today announced that it has received CE Mark approval for its Monarch eTNS System® as treatment for...

May 04, 2015, 07:00 ET

NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting

 NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company, today announced that results of an animal study of its...

Jan 06, 2015, 07:00 ET

FDA Grants NeuroSigma Humanitarian Use Device (HUD) Designation

NeuroSigma®, Inc. (NeuroSigma) today announced that it has received a Humanitarian Use Device (HUD) designation from the Food and Drug...

Jan 05, 2015, 07:00 ET

UCLA Launches Phase II Pediatric Clinical Trial for the Treatment of ADHD with NeuroSigma's eTNS System

 NeuroSigma®, Inc. (NeuroSigma) today announced that enrollment has commenced for a 90-subject Phase II pediatric clinical trial of its...

Nov 19, 2014, 07:00 ET

NeuroSigma Congratulates Brazilian Medical Team for Their Top-Line Results in Phase II Clinical Trial of eTNS for Treatment of Depression

 NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive external...

Nov 17, 2014, 07:00 ET

NeuroSigma Announces Top-Line Findings of UCLA Phase II Clinical Trial of eTNS for the Treatment of Depression

 NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS...

Nov 03, 2014, 07:00 ET

NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS)

 NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS...

Oct 21, 2014, 07:00 ET

NeuroSigma Receives Notice of Allowance of U.S. Patent Application

LOS ANGELES, Oct. 21, 2014 /PRNewswire/ – NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on...

Oct 15, 2014, 07:00 ET

NeuroSigma and the U.S. Veterans Administration (VA) Enter into Cooperative Research and Development Agreement (CRADA)

 NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS...

Aug 26, 2014, 18:45 ET

NeuroSigma, Inc. Files Registration Statement for Proposed Initial Public Offering

 NeuroSigma, Inc., a Los Angeles-based life sciences company established to develop bioelectronic technologies, today announced that it has...

Aug 25, 2014, 07:00 ET

U.S. Army Funds Phase II Clinical Trial at UCLA for the Treatment of PTSD with the NeuroSigma eTNS System

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™...

Jul 22, 2014, 07:00 ET

Enrollment Commences in NeuroSigma-Sponsored Pediatric Clinical Trial for the Treatment of Lennox-Gastaut Syndrome

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Jul 09, 2014, 07:00 ET

NIH Funds Phase 2 Clinical Trial at UCLA for the Treatment of ADHD with NeuroSigma's eTNS System

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Jul 08, 2014, 07:00 ET

Advances in Trigeminal Nerve Stimulation Featured at European Congress on Epileptology in Stockholm, Sweden

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Jun 03, 2014, 07:00 ET

Leading UCLA Physician Dr. Ian Cook Joins NeuroSigma As Chief Medical Officer and Senior Vice President

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Apr 01, 2014, 07:00 ET

NeuroSigma Receives Approval from Australian Therapeutic Goods Administration to Market its Monarch™ eTNS™ System for the Adjunctive Treatment of Drug-Resistant Epilepsy

 NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System...

Mar 28, 2014, 07:00 ET

NeuroSigma Expands Its Management Team with Two Former Amgen Finance Executives

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Feb 25, 2014, 07:00 ET

David Hayes, Former Partner at O'Melveny & Myers LLP and Haynes and Boone LLP, Joins NeuroSigma As Chief Administrative Officer, General Counsel and Sr. Vice President

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...

Feb 11, 2014, 06:00 ET

Former Amgen Finance Executive Carl Adams Joins NeuroSigma As Vice President and Controller

 NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™...